Biopharma Sales Executive – San Francisco
About the Role
The Biopharma Sales Executive will drive growth across biopharma accounts in North America. Acting as a technical sales specialist, this individual will collaborate with regional sales teams to identify new buying centers, expand existing relationships, and win complex, high-value opportunities.
The role will engage customers across R&D laboratories, core facilities, clinical research organizations, and biopharma manufacturing environments. It will also contribute to the broader commercial strategy for the biopharma segment.
Key Responsibilities
Qualifications
About Us
Oxford Nanopore has developed a new generation of nanopore-based sensing technology for faster, information-rich, accessible and affordable molecular analysis. The technology is used to understand and characterise the biology of humans, animals, plants, bacteria, viruses, and diseases such as cancer. By enabling biological insights, we strive to improve life on Earth and beyond.
The salary for this role is between $136,000 and $180,000 USD. The salary offered will reflect the skills and experience of the candidate. Certain roles within ONT are eligible for annual bonus and stock. These awards are allocated based on individual performance. Employees based in the US have the option to choose healthcare benefits, participate in the company 401(k) plan and company match, we also offer short-term and long-term disability coverage, basic life insurance, and commuter benefits to name a few.
We are proud to be an equal opportunity employer. We select and employ candidates only in accordance with their merits, qualifications, and abilities to perform the duties of the job regardless of gender, marital status, race, religion, color, age, disability, sexual orientation, military or veteran status. If you require an accommodation to complete the application or interview process, please contact human.resources@nanoporetech.com
#LI-Remote #LI-SH1
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
